Oncothyreon appoints Steven James to board
This article was originally published in Scrip
Executive Summary
Seattle's Oncothyreon has appointed Steven P James to its board of directors. Mr James most recently served as president and CEO of Labrys Biologics, from December 2012 until its acquisition by Teva in July 2014.